Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
- PMID: 33868163
- PMCID: PMC8044543
- DOI: 10.3389/fendo.2021.609470
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
Abstract
The pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has involved more than one hundred million individuals, including more than two million deaths. Diabetes represents one of the most prevalent chronic conditions worldwide and significantly increases the risk of hospitalization and death in COVID-19 patients. In this review, we discuss the prevalence, the pathophysiological mechanisms, and the outcomes of COVID-19 infection in people with diabetes. We propose a rationale for using drugs prescribed in patients with diabetes and some pragmatic clinical recommendations to deal with COVID-19 in this kind of patient.
Keywords: COVID-19; SARS-CoV-2; chronic conditions; coronavirus; diabetes; review.
Copyright © 2021 Corrao, Pinelli, Vacca, Raspanti and Argano.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- World Health Organization Director-General’s Opening Remarks at the Media Briefing on COVID-19–11 (2020).
-
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract (2019) 157:107843. 10.1016/j.diabres.2019.107843 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
